"L’établissement regroupe les services de gynécologie-obstétrique et de soins médicaux-chirurgicaux de l’enfant. Avec 3 800 accouchements/an, sa maternité de niveau 3 la plus importante de Bretagne offre des services de qualité pour une prise en charge globale : service de grossesses à risque, service de suivi ambulatoire de grossesse, unité Kangourou mère-enfant, 3 unités de suites de naissances et une filière physiologique "La Bulle", accompagnement au domicile des accouchées demandant une sortie à 48h, centre de diagnostic prénatal, service de néonatalogie, pédiatrie générale et de spécialités… ll accueille aussi les urgences gynécologiques, obstétricales et pédiatriques, un centre de ressources et de compétence de la mucoviscidose.."

During the past decade, CHU de Rennes - Hôpital Sud conducted 32 clinical trials. In the 10-year time frame, 32 clinical trials started and 5 clinical trials were completed, i.e. on average, 15.6% percent of trials that started reached the finish line to date. In the past 5 years, 12 clinical trials started and 5 clinical trials were completed. i.e. 41.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "CHU de Rennes - Hôpital Sud" #1 sponsor was "Centre Oscar Lambret" with 4 trials, followed by "University Hospital, Toulouse" with 4 trials sponsored, "Assistance Publique - Hôpitaux de Paris" with 3 trials sponsored, "Institut Curie" with 3 trials sponsored and "Institut National de la Santé Et de la Recherche Médicale, France" with 3 trials sponsored. Other sponsors include 37 different institutions and companies that sponsored additional 36 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "CHU de Rennes - Hôpital Sud" #1 collaborator was "Institut National de la Santé Et de la Recherche Médicale, France" with 3 trials as a collaborator, "National Cancer Institute, France" with 3 trials as a collaborator, "Celgene Corporation" with 2 trials as a collaborator, "ARCAGY/ GINECO GROUP" with 1 trials as a collaborator and "Australasian Leukaemia and Lymphoma Group" with 1 trials as a collaborator. Other collaborators include 32 different institutions and companies that were collaborators in the rest 42 trials.

According to Clinical.Site data, the most researched conditions in "CHU de Rennes - Hôpital Sud" are "Acromegaly" (3 trials), "Cystic Fibrosis" (2 trials), "Ewing Sarcoma Family of Tumors" (2 trials), "Lymphoma" (2 trials) and "Multiple Myeloma" (2 trials). Many other conditions were trialed in "CHU de Rennes - Hôpital Sud" in a lesser frequency.

Most popular intervention types in "CHU de Rennes - Hôpital Sud" are "Drug" (28 trials), "Other" (14 trials), "Biological" (8 trials), "Procedure" (7 trials) and "Device" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (6 trials), "Dexamethasone" (2 trials), "Etoposide" (2 trials), "bleomycin sulfate" (2 trials) and "doxorubicin hydrochloride" (2 trials). Other intervention names were less common.

The vast majority of trials in "CHU de Rennes - Hôpital Sud" are 50 trials for "All" genders, 8 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "CHU de Rennes - Hôpital Sud". 1 are not yet recruiting, 17 are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 27 completed trials in CHU de Rennes - Hôpital Sud, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in CHU de Rennes - Hôpital Sud, 2 "Phase 1" clinical trials were conducted, 13 "Phase 2" clinical trials and 16 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 5 trials, and there were also 13 trials that are defined as “Not Applicable".